Elk Creek Partners LLC raised its stake in shares of CryoLife, Inc. (NYSE:CRY) by 6.1% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 527,328 shares of the medical equipment provider’s stock after purchasing an additional 30,411 shares during the period. Elk Creek Partners LLC owned 1.58% of CryoLife worth $10,520,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the stock. Louisiana State Employees Retirement System raised its position in CryoLife by 0.9% during the 2nd quarter. Louisiana State Employees Retirement System now owns 11,100 shares of the medical equipment provider’s stock worth $221,000 after purchasing an additional 100 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its position in CryoLife by 3.2% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock worth $102,000 after purchasing an additional 190 shares during the last quarter. Arizona State Retirement System raised its position in CryoLife by 1.4% during the 1st quarter. Arizona State Retirement System now owns 14,054 shares of the medical equipment provider’s stock worth $234,000 after purchasing an additional 200 shares during the last quarter. Creative Planning raised its position in CryoLife by 3.0% during the 2nd quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock worth $136,000 after purchasing an additional 200 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in CryoLife by 0.9% during the 2nd quarter. Wells Fargo & Company MN now owns 31,313 shares of the medical equipment provider’s stock worth $624,000 after purchasing an additional 271 shares during the last quarter. 68.85% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Elk Creek Partners LLC Has $10.52 Million Position in CryoLife, Inc. (CRY)” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/17/elk-creek-partners-llc-has-10-52-million-position-in-cryolife-inc-cry.html.

Shares of CryoLife, Inc. (NYSE CRY) traded down 1.52% on Friday, reaching $22.70. The company had a trading volume of 1,002,111 shares. The company has a market capitalization of $759.22 million, a PE ratio of 68.79 and a beta of 0.97. The company’s 50-day moving average is $19.94 and its 200-day moving average is $18.37. CryoLife, Inc. has a one year low of $14.03 and a one year high of $23.35.

CryoLife (NYSE:CRY) last posted its quarterly earnings results on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.02. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The business had revenue of $47.80 million during the quarter, compared to analyst estimates of $47.02 million. During the same period in the prior year, the business posted $0.13 earnings per share. The company’s revenue was up 1.5% on a year-over-year basis. Equities research analysts predict that CryoLife, Inc. will post $0.43 earnings per share for the current year.

In other CryoLife news, VP Amy Horton sold 9,577 shares of the company’s stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $20.00, for a total transaction of $191,540.00. Following the completion of the sale, the vice president now directly owns 112,282 shares in the company, valued at $2,245,640. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO James P. Mackin sold 125,000 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $22.01, for a total transaction of $2,751,250.00. Following the sale, the chief executive officer now owns 398,399 shares of the company’s stock, valued at $8,768,761.99. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 178,627 shares of company stock valued at $3,915,765. Company insiders own 6.00% of the company’s stock.

Several research analysts recently issued reports on the company. Zacks Investment Research raised CryoLife from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. BidaskClub lowered CryoLife from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $22.00.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.